This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
E2F3 · Western blot design guide
E2F3 Western Blot Planning Guide
Plan a E2F3 Western blot around the catalog-observed 49.2 kDa band, image-backed A03068 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
E2F3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 49.2 kDa observed | |
| Observed band | 49.2 kDa observed | |
| Gel | 12-15% | |
| Positive control | No defensible HPA tissue; use knockout/knockdown | |
| Negative control | Use knockout/knockdown or orthogonal negative |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 49.2 kDa |
| ⓘ | Localization | Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated E2F3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Known-positive human lysate |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A03068 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected E2F3 Western Blot Band Size?
Use the product-observed 49.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 49.2 kDa | Matches the authoritative product WB observation. |
| 49.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected E2F3 appearancePlan around 49.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 49.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 49.2 kDa from UniProt O00716; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A03068. |
| Situation | Likely cause | Next action |
|---|---|---|
| 49.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing E2F3 band
A03068 · E2F3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for E2F3 Western blot
🧪No defensible HPA positive control was available; do not invent one.
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for E2F3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|
Section 3
Advanced E2F3 Western Blot Tips
Deeper troubleshooting and optimisation questions for E2F3, answered from its protein features.
Which band should guide the blot?
Use 49.2 kDa, the observation attached to the authoritative A03068 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 49.2 kDa expectation.
Which positive control should I start with?
No defensible positive tissue was supplied; do not invent one.
Which negative control is defensible?
Use a target knockdown/knockout control when no HPA Not detected tissue is available.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for E2F3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03068 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
E2F3 Western Blot Reagents
Human/Mouse/Rat-reactive E2F3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-E2F3 Antibody Picoband®
Cat # A03068
Real WB data
Anti-E2F3 Antibody Picoband®
Cat # A03068-2
Real WB data
Anti-E2F3 Antibody Picoband®
Cat # A03068-3
Real WB data
Anti-E2F3 Antibody Picoband®
Cat # A03068-4
Real WB data
Anti-Transcription factor E2F3 E2F3 Antibody Picoband®
Cat # PA2142
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O00716
- A03068 product record
- PMC10258005 — Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway (Aging, 2023)
- PMC7372943 — MicroRNA-770-5p contributes to podocyte injury via targeting E2F3 in diabetic nephropathy (Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2020)
- PMC9346169 — A novel circ_0000654/miR-375/E2F3 ceRNA network in esophageal squamous cell carcinoma (Thoracic cancer, 2022)